University of British Columbia, Vancouver, Canada.
J Endourol. 2010 Jun;24(6):1023-9. doi: 10.1089/end.2009.0523.
Ureteral stents often cause significant patient morbidity that can be difficult to treat. Drug-eluting stent technology allows the local delivery of a drug. Our previous work demonstrated that ketorolac instilled intravesically at the time of ureteral stent insertion significantly decreased flank pain compared with controls. We sought to determine the safety of a novel ketorolac-eluting ureteral stent.
A total of 92 Yorkshire pigs were randomized to 1 of 5 groups. The oral control group consisted of 12 animals with transurethrally inserted control ureteral stents and 5 days of oral ketorolac. Twenty animals in each of the remaining groups received a control stent, or 15%, 13%, or 7% ketorolac-loaded stents. Ketorolac levels were measured in plasma, urine, and tissue sampled from ureters, bladder, kidneys, and liver using high performance liquid chromatography. Necropsies were performed to evaluate tissue pathology.
The majority of ketorolac was released within the first 30 days. The highest levels of ketorolac in plasma, kidney, and liver occurred in the oral control group. The highest levels of ketorolac found in ureteral and bladder tissues occurred in the ketorolac-stent groups in a dose-dependent fashion. No adverse events were noted in any of the ketorolac-stent groups. Gastric ulcerations were identified only in the oral control group. No abnormalities were identified in any other internal organs in any group.
The use of ketorolac-eluting ureteral stents has proven to be safe in a porcine model. The ketorolac-stent group had less than 12% of the ketorolac concentration in plasma, kidney, and liver tissues compared with the oral ketorolac group. Ureteral tissues displayed the highest levels of ketorolac. Clinical studies are needed to determine if ketorolac-elution reduces stent symptoms.
输尿管支架常导致严重的患者发病率,且难以治疗。药物洗脱支架技术允许局部递送药物。我们之前的工作表明,在输尿管支架置入时向膀胱内注入酮咯酸可显著降低腰痛与对照组相比。我们旨在确定新型酮咯酸洗脱输尿管支架的安全性。
共 92 头约克夏猪随机分为 5 组中的 1 组。口服对照组包括 12 只经尿道插入的对照输尿管支架和 5 天的口服酮咯酸。其余每组各有 20 只动物接受对照支架或 15%、13%或 7%载有酮咯酸的支架。使用高效液相色谱法测量从输尿管、膀胱、肾脏和肝脏中取样的血浆、尿液和组织中的酮咯酸水平。进行尸检以评估组织病理学。
大多数酮咯酸在最初 30 天内释放。血浆、肾脏和肝脏中的酮咯酸含量最高的是口服对照组。在输尿管和膀胱组织中发现的最高浓度的酮咯酸以剂量依赖的方式出现在酮咯酸支架组中。在任何酮咯酸支架组中均未发现不良事件。仅在口服对照组中发现胃溃疡。在任何一组中均未发现其他内部器官的异常。
在猪模型中,使用酮咯酸洗脱输尿管支架已被证明是安全的。与口服酮咯酸组相比,酮咯酸支架组的血浆、肾脏和肝脏组织中的酮咯酸浓度低于 12%。输尿管组织显示出最高水平的酮咯酸。需要进行临床研究以确定酮咯酸洗脱是否可以减轻支架症状。